Trial Profile
A phase I trial of BIA 102474
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs BIA 102474 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- 17 May 2021 Results published in the Clinical Pharmacology and Therapeutics
- 10 Mar 2016 New trial record
- 19 Jan 2016 According to BIAL media release, as of June 2015, the French Regulatory Authorities and by the French Ethics Committee, in accordance with Good Clinical Practices, with the Declaration of Helsinki and the inherent clinical trials related legislation approved for this trial but BIAL was informed about the occurrence of an adverse effect in a volunteer on the 11th January, BIAL immediately decided to discontinue the medication to all the participants in the trial.